Mounjaro KWIKPEN 2.5mg (Tirzepatide Injection) 2.5 MG/0.6 ML(2.4 ML)

Mounjaro KWIKPEN 2.5mg is utilized in the management of type 2 diabetes mellitus, a chronic condition characterized by high blood sugar levels. It is indicated for use in adults who have not achieved adequate glycemic control with diet and exercise alone.

• Type 2 diabetes mellitus: Helps improve glycemic control in adults with type 2 diabetes when used in conjunction with diet and exercise.

• Tirzepatide, the active ingredient in Mounjaro KWIKPEN 2.5mg, activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, reduces glucagon release, and slows gastric emptying, thereby improving glycemic control and promoting weight loss.

Mounjaro KWIKPEN 2.5mg may cause various side effects, ranging from common to serious or rare. Patients should be aware of these potential adverse reactions and consult their healthcare provider if they experience any severe or persistent symptoms.

Common Side Effects

• Nausea: A common gastrointestinal side effect that may occur during treatment.
• Vomiting: Another gastrointestinal side effect that can occur.
• Diarrhea: May be experienced by some patients.
• Constipation: Can also be a side effect of the medication.
• Injection site reactions: Redness, swelling, or itching at the injection site.
• Decreased appetite: May lead to reduced food intake.

Serious or Rare Side Effects

• Pancreatitis: Inflammation of the pancreas, which can be serious.
• Hypoglycemia: Low blood sugar levels, especially when used with other antidiabetic medications.
• Kidney problems: May include kidney failure or worsening of existing kidney disease.
• Allergic reactions: Severe allergic reactions, including anaphylaxis, are rare but possible.

Mounjaro KWIKPEN 2.5mg should be used with caution, and certain precautions should be observed to ensure safe and effective treatment. Patients should follow their healthcare provider's instructions and be aware of potential risks.

• Avoid use in patients with a personal or family history of medullary thyroid carcinoma: Tirzepatide should not be used in patients with a history of this type of thyroid cancer.
• Monitor for signs of pancreatitis: Patients should be monitored for symptoms such as severe abdominal pain, nausea, and vomiting.
• Use with caution in patients with a history of severe gastrointestinal disease: May exacerbate existing gastrointestinal conditions.
• Monitor for signs of hypoglycemia: Especially when used in combination with other antidiabetic medications.
• Inform healthcare provider of all medications being taken: To avoid potential drug interactions.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Mounjaro KWIKPEN 2.5mg may interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Patients should inform their healthcare provider of all medications they are taking to avoid adverse interactions.

Major Interactions (Avoid)

• Insulin: Concurrent use may increase the risk of hypoglycemia.
• Sulfonylureas: May also increase the risk of hypoglycemia when used together.
• Other GLP-1 receptor agonists: May enhance the risk of gastrointestinal side effects.

Moderate Interactions (Monitor Closely)

• Oral medications: May affect the absorption of oral medications due to delayed gastric emptying.
• Diuretics: May increase the risk of dehydration and kidney problems.
• Corticosteroids: May increase the risk of hyperglycemia.